{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:27:48Z","timestamp":1790724468335,"version":"4.1.0"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Atea Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2023,8,17]]},"abstract":"<jats:p>\n            COVID-19 continues to be a major global public health challenge, and there remains a need for effective and convenient direct-acting antivirals that can be administered outside health care settings. Bemnifosbuvir is an oral antiviral with a dual mechanism of action and potent\n            <jats:italic>in vitro<\/jats:italic>\n            activity against SARS-CoV-2.\n          <\/jats:p>","DOI":"10.1128\/spectrum.00077-23","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T14:05:53Z","timestamp":1687269953000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study)"],"prefix":"10.1128","volume":"11","author":[{"given":"Marta","family":"Boffito","sequence":"first","affiliation":[{"name":"Chelsea and Westminster Hospital NHS Foundation Trust London, United Kingdom"},{"name":"Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamon","family":"Dolan","sequence":"additional","affiliation":[{"name":"Connolly Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karishma","family":"Singh","sequence":"additional","affiliation":[{"name":"Tower Family Healthcare, Bury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Holmes","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Wildum","sequence":"additional","affiliation":[{"name":"Roche Pharma, Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Horga","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Pietropaolo","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Atea Pharmaceuticals, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Clinch","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Collinson","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-9105","authenticated-orcid":true,"given":"Vincent","family":"Ukachukwu","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Johns Hopkins University. 2022. COVID-19 dashboard. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 3 October 2022."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac279"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01531-3"},{"key":"e_1_3_3_5_2","unstructured":"Centers for Disease Control and Prevention. 2022. Symptoms of COVID-19. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html. Accessed 3 October 2022."},{"key":"e_1_3_3_6_2","unstructured":"European Medicines Agency. COVID-19 vaccines: key facts. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-key-facts. Accessed 3 October 2021."},{"key":"e_1_3_3_7_2","unstructured":"United States Food and Drug Administration. 2023. COVID-19 vaccines. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines#authorized-vaccines. Accessed 12 June 2023."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13040628"},{"key":"e_1_3_3_9_2","unstructured":"European Medicines Agency. 2022. Paxlovid: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid. Accessed 3 October 2022."},{"key":"e_1_3_3_10_2","unstructured":"European Medicines Agency. 2022. Veklury: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veklury. Accessed 3 October 2022."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7112e1"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068632"},{"key":"e_1_3_3_14_2","unstructured":"Centers for Disease Control and Prevention. 2022. Interim clinical considerations for use of COVID-19 vaccines in the United States. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#contraindications. Accessed 3 October 2022."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1138"},{"key":"e_1_3_3_16_2","unstructured":"GOV.UK. 2021. Government launches COVID-19 antivirals taskforce to roll out innovative home treatments this autumn. https:\/\/www.gov.uk\/government\/news\/government-launches-covid-19-antivirals-taskforce-to-roll-out-innovative-home-treatments-this-autumn. Accessed 3 October 2022."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n597"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2"},{"key":"e_1_3_3_19_2","unstructured":"United States Food and Drug Administration. 2022. Fact sheet for healthcare providers: emergency use authorization for paxlovid. https:\/\/www.fda.gov\/media\/155050\/download. Accessed 3 October 2022."},{"key":"e_1_3_3_20_2","unstructured":"United States Food and Drug Administration. 2022. Veklury prescribing information. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/covid-19\/veklury\/veklury_pi.pdf. Accessed 3 October 2022."},{"key":"e_1_3_3_21_2","unstructured":"U.S. Food and Drug Administration. 2021. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain. Accessed 3 October 2022."},{"key":"e_1_3_3_22_2","unstructured":"Medicines and Healthcare Products Regulatory Agency. 2022. Lagevrio: summary of product characteristics. https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-lagevrio-molnupiravir\/summary-of-product-characteristics-for-lagevrio. Accessed 3 October 2022."},{"key":"e_1_3_3_23_2","unstructured":"World Health Organization. 2022. Therapeutics and COVID-19: living guideline 26 September 2022. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.5. Accessed 3 October 2022."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108163"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220908"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl7430"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac320"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02479-20"},{"key":"e_1_3_3_33_2","article-title":"AT-527 achieves antiviral concentrations in the human lung [poster 136]","author":"Zhou X-J","year":"2021","unstructured":"Zhou X-J, Horga A, Puri A, Montrond M, Espi\u00e9 P, Pietropaolo K, Belanger B, Hammond J. 2021. AT-527 achieves antiviral concentrations in the human lung [poster 136]. COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment (ISIRV-WHO Virtual Conference), 19\u201321 October 2021.","journal-title":"COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment (ISIRV-WHO Virtual Conference)"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","unstructured":"Shannon A Fattorini V Sama B Selisko B Feracci M Falcou C Gauffre P El Kazzi P Decroly E Rabah N Alvarez K Eydoux C Guillemot J-C Debart F Vasseur J-J Noel M Moussa A Good S Lin K Sommadossi J-P Zhu Y Yan X Shi H Ferron F Canard B. 2021. Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527. BioRxiv. doi:10.1101\/2021.03.23.436564.","DOI":"10.1101\/2021.03.23.436564"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2608.201246"},{"key":"e_1_3_3_36_2","unstructured":"U.S. Food and Drug Administration. 2020. Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment: guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs. Accessed 3 October 2022."}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00077-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00077-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T13:17:36Z","timestamp":1692278256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.00077-23"}},"subtitle":[],"editor":[{"given":"Oliver","family":"Laeyendecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8,17]]}},"alternative-id":["10.1128\/spectrum.00077-23"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.00077-23","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"2023-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00077-23"}}